Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma completed its share buy-back program on October 5, ahead of the October 31 deadline, after repurchasing 4,408,500 shares for DKK 1,299,996,125 at an average DKK 294.88 per share. The total consideration was approximately DKK 1.3 billion. Following the transactions, the company holds 5,279,342 treasury shares, or approximately 7.37% of its share capital.

Analysis

The key change is the removal of a known, price-insensitive source of demand—not a new improvement in Zealand Pharma’s drug economics. The DKK 1.3bn authorization is exhausted, so investors should not extrapolate the program’s purchases as a continuing floor. The late-program executions around DKK 249–267 also sit below the DKK 294.88 program-wide average; that average is historical execution, not evidence of intrinsic value or a reliable support level.

The 5.28m treasury shares (about 7.37% of share capital) make the next capital-allocation decision material. Cancellation could shrink the share base; retention or later resale would have different float implications. The announcement does not specify the disposition, and does not establish whether the buyback altered R&D funding capacity. Verify cash, expected development spend, and board plans before drawing conclusions about balance-sheet risk.

Near term, the mechanical bid disappearing may expose ZEAL to ordinary biotech volatility, but this release alone is not a fundamental short signal. Over 1–3 months, clinical or partnership news should dominate; over 6–18 months, the opportunity cost of returning capital rather than funding pipeline development matters if cash is constrained. Contrarian point: completion ahead of the original deadline reflects reaching the stated aggregate amount, not necessarily management conviction about undervaluation. No clear read-through to Danske Bank: it acted as independent manager, and the announcement provides no basis to infer material earnings impact.

Key Decisions for Investors

• Do not treat the buyback’s DKK 294.88 average as a valuation anchor or assume the bid continues. Avoid initiating a directional ZEAL position solely on this announcement; assess the stock’s post-completion price and volume against pipeline catalysts.
• Alert: verify whether Zealand Pharma will cancel, retain, or potentially reissue the treasury shares, and review cash plus clinical-development commitments. A cancellation would support per-share math; evidence that capital returns constrain pipeline investment would weaken the longer-term thesis.
• For existing ZEAL exposure, reassess sizing against upcoming clinical and partnership catalysts rather than the buyback. Falsification of the near-term ‘support removed’ concern would be stable trading after program completion; sustained weakness alone is not confirmation without a catalyst or guidance change.